ライフサイエンスコーパス: saphenous

1 to facilitate placement of sutureless aorto-saphenous anastomoses during off-pump coronary artery by

2 ression through Rho-kinase, we exposed human saphenous and pulmonary artery endothelial cells to hypo

3 mean caliber of myelinated axons in both the saphenous and sciatic nerves was reduced in galactose-in

4 In the largely cutaneous saphenous and sural nerves, the naked mole-rat had the l

5 d mouse skeletal muscle arterioles and mouse saphenous arteries were isolated, pressurized, and subje

6 (gAd) and insulin on pre-constricted distal saphenous arteries.

7 s 30% for popliteal arteries, 45% vs 28% for saphenous arteries; P < .001 for both comparisons) and e

8 eparin to inhibit intimal hyperplasia in the saphenous artery of the baboon after balloon angioplasty

9 n tension were determined in isolated distal saphenous artery.

10 those that use catheters to occlude straight saphenous axes (thermal / non-thermal ablation) and othe

11 in penile cancer and the Nesbit operation or saphenous grafting for Peyronie's disease.

12 patients (3.51%) (25.1% mediastinitis, 32.6% saphenous harvest site, 35.0% septicemia, 0.5% thoracoto

13 CN), left dorsal collector nerve (DCN), left saphenous nerve (SN) or left renal nerve (RN).

14 in myelinated axons in the mid-shaft of the saphenous nerve and in the sensory ganglion cells.

15 nd hairy hindpaw skin at various times after saphenous nerve axotomy suggested multiple changes in ne

16 reventing movement-induced afferent input by saphenous nerve block before, but not after, hindlimb mo

17 cancer learn to prefer a context paired with saphenous nerve block to elicit pain relief (i.e., condi

18 ment with systemic morphine abolished CPP to saphenous nerve block, demonstrating control of ongoing

19 Injection of Sox11 siRNAs into the mouse saphenous nerve caused a transient knockdown of Sox11 mR

20 ation of capsaicin to skin innervated by the saphenous nerve increased mitochondrial traffic in both

21 tron microscopy, we recently showed that the saphenous nerve of the naked mole-rat (Heterocephalus gl

22 llular recordings of single neurons from the saphenous nerve of vincristine-treated rats.

23 s of hairy hindpaw skin and L2/L3 DRGs after saphenous nerve regeneration suggested that inhibition o

24 nges in mouse cutaneous CH neurons following saphenous nerve regeneration.

25 We have shown recently that following saphenous nerve transection and successful regeneration,

26 rs after transection and regeneration of the saphenous nerve.

27 Saphenous nerves and spinal roots of anaesthetized trans

28 ive adult axons in vivo, confocal imaging of saphenous nerves in anaesthetised mice was combined with

29 eralgesia, we analyzed unmyelinated axons in saphenous nerves of vincristine-treated rats.

30 ed in the galactose group, while sciatic and saphenous sensory NCVs were not significantly changed.

31 d 20 and 16% reductions in sciatic motor and saphenous sensory nerve conduction velocity, which were

32 ammary artery (6.2+/-0.3 pmol/mg protein) or saphenous vein (1.4+/-0.2 pmol/mg protein, both P<0.05).

33 ammary artery (3.5+/-1.3 pmol/mg protein) or saphenous vein (1.4+/-0.3 pmol/mg protein, both P<0.0001

34 er than internal mammary artery (56+/-9%) or saphenous vein (11+/-5%, both P<0.0001).

35 %) than internal mammary artery (23+/-6%) or saphenous vein (5+/-2%, both P<0.05).

36 internal mammary artery (203+/-32 nmol/L) or saphenous vein (97+/-12 nmol/L, both P<0.05).

37 cantly augmented BH4 levels in plasma and in saphenous vein (but not internal mammary artery) but als

38 utive patients with primary unilateral great saphenous vein (GSV) reflux undergoing endovenous treatm

39 Standard harvest and preparation of human saphenous vein (HSV) for autologous coronary and periphe

40 ue with a cumulative manner in ex vivo human saphenous vein (HSV) model.

41 Aged, diseased, human saphenous vein (HSV) remnants obtained from patients und

42 n macrovascular endothelial cells from human saphenous vein (HSVEC).

43 ion of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated N

44 cation to the carotid artery (high shear) or saphenous vein (lower shear); hyperfibrinogenemia signif

45 The long saphenous vein (LSV) is commonly used as a conduit in co

46 mutation in FOXC2 showed reflux in the great saphenous vein (n=18), compared with only 1 of 12 refere

47 radial artery, internal mammary artery, and saphenous vein (n=24 patients) were examined by use of o

48 , and venous surgery not involving the great saphenous vein (OR = 15.61, P < 0.001).

49 - 0.2% for the RA, and 55.0 +/- 0.2% for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.1

50 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

51 trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is n

52 on is associated with intimal hyperplasia in saphenous vein (SV) bypass grafts.

53 operation: 2,389 had LITA grafting and 1,084 saphenous vein (SV) grafting to the LAD.

54 have significantly better patency rates than saphenous vein (SV) grafts at 5 years, but the physiolog

55 y artery, internal mammary artery (IMA), and saphenous vein (SV).

56 ight internal thoracic artery (RITA) and the saphenous vein (SV).

57 profiles of primary cultured ECs from human saphenous vein (SVEC) and coronary artery (CAEC) exposed

58 that this axis behaves the same as the great saphenous vein after treatment.

59 that this axis behaves the same as the great saphenous vein after treatment.

60 ynthase (eNOS) uncoupling were quantified in saphenous vein and internal mammary artery segments.

61 ivo release were quantified in perivascular (saphenous vein and internal mammary artery) subcutaneous

62 nd BH4 levels were determined in segments of saphenous vein and internal mammary artery.

63 eceptors were shown to be expressed in human saphenous vein and internal mammary artery.

64 imately 90% and 50% of cells in intact human saphenous vein and rat myocardium, respectively.

65 d during stenting in 22 patients with severe saphenous vein aorto-coronary bypass stenoses.

66 he angiographic patency of radial artery and saphenous vein aortocoronary bypass grafts at 5 years af

67 bosis, which is the final common pathway for saphenous vein arterial bypass graft occlusion.

68 rimary, isolated CABG with the LITA, RA, and saphenous vein as needed.

69 arameters of material obliterating the great saphenous vein at 7-21 days after polidocanol sclerother

70 nous enhancement (99 HU) was observed in the saphenous vein at the ankle, with all other venous stati

71 prophylactic therapy (testing hemostasis by saphenous vein bleeding 7 days after infusion of 150 IU/

72 he level of FVIIa needed for hemostasis in a saphenous vein bleeding assay.

73 Here, we use the saphenous vein bleeding model to compare the efficacy of

74 The use of aortic connectors for proximal saphenous vein bypass graft anastomoses eliminates the n

75 utaneous revascularization (PCI) of diseased saphenous vein bypass grafts (SVGs).

76 At angiography, 20 saphenous vein bypass grafts containing 19 connectors we

77 me has been disappointing so far, except for saphenous vein bypass grafts.

78 ase as the quest for an alternative graft to saphenous vein continues.

79 Results from a functional assay (rabbit saphenous vein contraction) demonstrate that certain dim

80 Autologous saphenous vein coronary artery bypass graft surgery is c

81 complications during stenting of degenerated saphenous vein coronary bypass grafts are reduced, but n

82 nstable angina, peripheral arterial disease, saphenous vein coronary bypass grafts, and diabetic reti

83 ine the effects of MARCKS silencing in human saphenous vein cultured ex vivo.

84 Primary cultures of human saphenous vein endothelial cells (ECs) and vascular smoo

85 ere incubated with IFN-gamma-activated human saphenous vein endothelial cells (HSVEC), but not with r

86 in bovine aortic endothelial cells and human saphenous vein endothelial cells in vitro and in adult m

87 to human erythroleukemia cells and to human saphenous vein endothelial cells was mediated by both al

88 Human saphenous vein endothelial cells were treated with ox-LD

89 ls of the hH1 isoform are expressed in human saphenous vein endothelium and that the presence of thes

90 In saphenous vein endothelium exposed to arterial flow cond

91 tion suppressed vascular remodeling of human saphenous vein explants ex vivo.

92 ve resulted in more favorable outcomes after saphenous vein graft (SVG) angioplasty.

93 stent implantation versus stenting alone for saphenous vein graft (SVG) aortoostial lesions.

94 The pattern of saphenous vein graft (SVG) calcification before percutan

95 aft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unk

96 t of creatine kinase (CK-MB) elevation after saphenous vein graft (SVG) intervention is high, its pro

97 use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studie

98 We sought to examine saphenous vein graft (SVG) lesions that fail within the

99 sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting ste

100 PES) and a similar bare-metal stent (BMS) in saphenous vein graft (SVG) lesions.

101 et effect of aspirin, or both, contribute to saphenous vein graft (SVG) occlusion after coronary arte

102 pose of this study was to present radial and saphenous vein graft (SVG) occlusion results more than 5

103 assess disease progression in nonintervened saphenous vein graft (SVG) segments to determine the nat

104 Treatment of saphenous vein graft (SVG) stenosis with percutaneous co

105 ectiveness of gamma-irradiation ((192)Ir) in saphenous vein graft (SVG) versus native coronary artery

106 cutaneous coronary intervention (PCI) of the saphenous vein graft (SVG).

107 20%) also received an RA graft instead of a saphenous vein graft (SVG).

108 ) or conventional treatment (n = 395) in the Saphenous Vein Graft Angioplasty Free of Emboli Randomiz

109 Saphenous vein graft angioplasty has been limited by hig

110 g-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospecti

111 ient and SVG characteristics associated with saphenous vein graft atherosclerosis progression.

112 Angiographic changes in saphenous vein graft conduits 4.3 years after entry were

113 lower FitzGibbon A patency for arterial and saphenous vein graft conduits and less effective revascu

114 bolysis in 39%, cardiogenic shock in 17% and saphenous vein graft culprit in 11% of patients.

115 e use of a radial artery graft compared with saphenous vein graft did not result in greater 1-year pa

116 sis, bifurcation lesions, left main disease, saphenous vein graft disease, and acute coronary syndrom

117 ve coronary arteries, inhibit the process of saphenous vein graft disease, and improve vein graft pat

118 Aortocoronary saphenous vein graft disease, with its increasing clinic

119 tionship may also be seen after treatment of saphenous vein graft disease.

120 feration of the intima is an early lesion of saphenous vein graft disease.

121 High success was achieved in the saphenous vein graft group.

122 The Protection During Saphenous Vein Graft Intervention to Prevent Distal Embo

123 When saphenous vein graft interventions were excluded, howeve

124 During saphenous vein graft interventions, particulate retrieve

125 essels, long coronary stenoses, and possibly saphenous vein graft interventions.

126 omes of embolic protection devices (EPDs) in saphenous vein graft interventions.

127 ative coronary artery stenoses (CAVEAT-I) or saphenous vein graft lesions (CAVEAT-II) were randomized

128 oronary artery bypass grafting and >1 target saphenous vein graft lesions were associated with increa

129 undergoing percutaneous intervention of 682 saphenous vein graft lesions were prospectively randomiz

130 ocation (78.6% in left main lesion, 69.7% in saphenous vein graft lesions, 42.4% in circumflex lesion

131 ercutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in

132 We recently demonstrated in a pig saphenous vein graft model that application of an extern

133 In patients undergoing DCA or PTCA of saphenous vein graft narrowings, the relationship betwee

134 h platelet activation (deep vein thrombosis; saphenous vein graft occlusion after coronary bypass sur

135 In contrast, saphenous vein graft patency declined over time and simi

136 ular CABG trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coro

137 We identified patients undergoing isolated saphenous vein graft percutaneous coronary intervention

138 tion or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention

139 s to improve outcomes among those undergoing saphenous vein graft percutaneous coronary intervention.

140 ic protection device use during contemporary saphenous vein graft percutaneous coronary intervention.

141 eft internal mammary artery), reperfusion B (saphenous vein graft perfusion).

142 Saphenous vein graft stenosis is a significant clinical

143 uardWire balloon or a vascular filter during saphenous vein graft stenting.

144 A saphenous vein graft to an important or less important t

145 otection filter devices during uncomplicated saphenous vein graft, carotid, renal, and superficial fe

146 nt vessel was randomized to radial artery vs saphenous vein graft.

147 ere administered into the coronary artery or saphenous vein graft.

148 hen the infarct-related vessel is a diseased saphenous vein graft.

149 of retrograde CTO PCI via patent or occluded saphenous vein graft.

150 e center to have either the radial artery or saphenous vein grafted to a stenosed branch of the nativ

151 of patients undergoing a nonstaged multiple saphenous vein grafting (SVG) intervention with stents a

152 rteries (38.5%) and greater than that in new saphenous vein grafts (11.8%).

153 at the feasibility and safety of CTO PCI via saphenous vein grafts (19% of post-CABG cases) versus co

154 ternal mammary arteries (90.3%, P<0.0001) or saphenous vein grafts (64.0%, P=0.0016).

155 l conduits (85.8% versus 91.4%; P=0.003) and saphenous vein grafts (72.7% versus 80.4%; P<0.001).

156 ernal thoracic artery (LITA) supplemented by saphenous vein grafts (LITA+SVG) has been demonstrated i

157 EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and we

158 enosis rate of 15.1%, compared with 5.9% for saphenous vein grafts (P=0.0003) and 4.8% for left inter

159 atent radial artery grafts and 23% of patent saphenous vein grafts (P=0.01).

160 ception of patients treated with degenerated saphenous vein grafts (risk with placebo 16.3% vs. risk

161 This study defined long-term patency of saphenous vein grafts (SVG) and internal mammary artery

162 l outcome after percutaneous intervention of saphenous vein grafts (SVG) and to identify the predicto

163 iabetic patients after stent implantation in saphenous vein grafts (SVG).

164 S) for percutaneous coronary intervention in saphenous vein grafts (SVG).

165 Stenosis of saphenous vein grafts (SVGs) after coronary artery bypas

166 tomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing nat

167 Saphenous vein grafts (SVGs) are effective in relieving

168 Intimal hyperplasia of saphenous vein grafts (SVGs) can lead to subsequent graf

169 Because saphenous vein grafts (SVGs) exhibit greater cellular he

170 Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically been assoc

171 terial grafts have better patency rates than saphenous vein grafts (SVGs) in coronary artery bypass g

172 Approximately 15% of saphenous vein grafts (SVGs) occlude during the first ye

173 In each patient, all saphenous vein grafts (SVGs) placed (n = 11) with the de

174 s related to successful stenting of diseased saphenous vein grafts (SVGs) using a novel filter-based

175 ercutaneous coronary interventions (PCIs) in saphenous vein grafts (SVGs) with thrombus have a high f

176 coronary interventions (PCIs) in degenerated saphenous vein grafts (SVGs) without distal embolic prot

177 before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-densi

178 ruptured atherosclerotic plaques detected in saphenous vein grafts (SVGs).

179 ffects, is expressed in "arterialized" human saphenous vein grafts (SVGs).

180 ith the highest 10-year patency rate (>90%), saphenous vein grafts - the most commonly used conduit i

181 gnificantly better than the patency rate for saphenous vein grafts and comparable to reported patency

182 er superior long-term survival compared with saphenous vein grafts and should be considered in patien

183 erosclerotic progression among patients with saphenous vein grafts and that aggressive lipid lowering

184 nct to percutaneous intervention of diseased saphenous vein grafts and, compared with distal protecti

185 Saphenous vein grafts are exposed to hemodynamic stress

186 To achieve high success rate, use of saphenous vein grafts as retrograde conduits seems to be

187 nt the latest evidence on the utilization of saphenous vein grafts for CABG surgery and provide an ov

188 rafts are thought to be better conduits than saphenous vein grafts for coronary artery bypass graftin

189 The PercuSurge GuardWire was used in 17 saphenous vein grafts in 16 patients.

190 istal pore size 100 microns) were used in 47 saphenous vein grafts in 44 patients.

191 after percutaneous intervention in diseased saphenous vein grafts is reduced by distal microcirculat

192 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

193 placebo on progression of atherosclerosis in saphenous vein grafts of patients who had had CABG surge

194 Interventions were performed on either saphenous vein grafts or native vessels and utilized ang

195 enever possible during treatment of diseased saphenous vein grafts produced outcomes similar to those

196 Implantation of saphenous vein grafts promotes upregulation of NADPH oxi

197 Saphenous vein grafts remain patent for approximately 10

198 rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending ve

199 Medical) was developed to rapidly anastomose saphenous vein grafts to the aorta during coronary bypas

200 Saphenous vein grafts used in coronary artery bypass gra

201 ; 98.3% of radial artery grafts and 86.4% of saphenous vein grafts were patent (P=0.04).

202 l of 594 patients undergoing stenting of 639 saphenous vein grafts were prospectively randomized, usi

203 Early and late patency of saphenous vein grafts were similar in patients with and

204 year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus singl

205 ger vessels, in the right coronary artery or saphenous vein grafts, and for unfavorable lesion charac

206 during percutaneous coronary intervention of saphenous vein grafts, but the use of these devices in c

207 xus and Cardiac Surgery) score, treatment of saphenous vein grafts, ostial lesions, and in-stent rest

208 anterior descending, right coronary artery, saphenous vein grafts, ostial lesions, or in-stent reste

209 ncy has been shown to be superior to that of saphenous vein grafts.

210 rates than left internal mammary artery and saphenous vein grafts.

211 reased the progression of atherosclerosis in saphenous vein grafts.

212 in-stent restenosis in native coronaries and saphenous vein grafts.

213 ors for a rapid atherosclerotic attrition of saphenous vein grafts.

214 the detrimental effect of atherosclerosis on saphenous vein grafts.

215 rnal thoracic artery (ITA) grafts and 20,066 saphenous vein grafts.

216 , or ostial; total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) fr

217 up reported significantly more pain than the saphenous vein group 3 months after surgery; however, si

218 (366 in the radial artery group, 367 in the saphenous vein group).

219 operative baseline between radial artery and saphenous vein groups after adjusting for covariates (P

220 e consequences of radial artery harvest with saphenous vein harvest in patients undergoing elective c

221 Use of endoscopic saphenous vein harvesting has developed into a routine s

222 The human saphenous vein has a greater propensity for intimal hype

223 function in normal and atherosclerotic human saphenous vein imply a role for the peptide in the progr

224 Using human saphenous vein in a validated ex vivo flow circuit, we i

225 ides superior long-term patency rates to the saphenous vein in most situations.

226 gulator of acute endothelial inflammation in saphenous vein in response to acute arterial WSS.

227 reduced the average time to hemostasis after saphenous vein incision, and the time to occlusion after

228 ure base, centered on the treatment of great saphenous vein incompetence cannot simply be extrapolate

229 ophilia B mice, the times to first clot at a saphenous vein injury site after the infusions of the FI

230 the time to occlusion after FeCl(3)-induced saphenous vein injury.

231 was to assess thrombus age in patients with saphenous vein insufficiency treated with sclerotherapy.

232 f stenotic coronary arteries with autologous saphenous vein is an established treatment for ischemic

233 Similar effects were observed in human saphenous vein medial segments where proliferation was r

234 F-positive MPs had increased thrombosis in a saphenous vein model.

235 analysis had radial artery only (n = 80) or saphenous vein only (n = 337) harvest.

236 atients enrolled in the Radial artery versus Saphenous Vein Patency (RSVP) trial.

237 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and

238 Patients with saphenous vein reflux undergoing treatment with endother

239 ility was evaluated by organ bath studies on saphenous vein rings.

240 rior descending artery, and radial artery or saphenous vein segments are used to graft the lateral an

241 l artery in vivo and by vasomotor studies in saphenous vein segments ex vivo.

242 nical significance was investigated by using saphenous vein segments from non-coronary heart disease

243 At operation, saphenous vein segments were explanted for VSMC culture.

244 growth factor-stimulated migration of human saphenous vein SMCs and decrease phosphorylation of the

245 We used deep RNA-sequencing of human saphenous vein SMCs stimulated with IL (interleukin)-1al

246 tudy, transient transfection assays in human saphenous vein smooth muscle cells (HSVSMC) and pulmonar

247 od or from adult peripheral blood, and human saphenous vein smooth muscle cells (HSVSMCs) as a source

248 n was increased in carotid atherectomies and saphenous vein specimens from diabetic versus nondiabeti

249 diabetic and nonischemic patients undergoing saphenous vein stripping were used.

250 Exposure of VSMCs derived from human saphenous vein to C pneumoniae EBs (3x10(7) inclusion fo

251 ncRNAs whose expression was altered in human saphenous vein vascular smooth muscle cells following st

252 -derived growth factor-BB (PDGF-BB) in human saphenous vein VSMCs.

253 uccessful ablation of the main trunks of the saphenous vein was less common in the foam group than in

254 = 65 years) in mammary artery (no change in saphenous vein), accompanied by increased alpha(1b)>alph

255 11 for RA vs. ITA, and p < 0.001 for ITA vs. saphenous vein).

256 for the saphenous vein (p = 0.002 for RA vs. saphenous vein, 0.11 for RA vs. ITA, and p < 0.001 for I

257 89%; 95% confidence interval [CI], 86%-93%; saphenous vein, 239/269; 89%; 95% CI, 85%-93%; adjusted

258 Adaptation of saphenous vein, with its intrinsic myogenic tone, from t

259 Compare the reparative potential of saphenous vein-derived pericytes (SVPs) with that of car

260 MT1-MMP expression in human saphenous vein-derived smooth muscle cells (SMCs) mainta

261 duced neointimal formation in cultured human saphenous vein.

262 e descended to the lower leg along the short saphenous vein.

263 panel graft constructed of recipient greater saphenous vein.

264 to those of the internal mammary artery and saphenous vein.

265 hich all others are compared--is the greater saphenous vein.

266 g-term patency of this conduit compared with saphenous vein.

267 ater than that of internal mammary artery or saphenous vein.

268 m aortic and coronary artery, as well as the saphenous vein.

269 reoperation over single thoracic artery with saphenous vein.

270 smooth muscle cells were cultured from human saphenous vein.

271 easured by thromboelastography and prolonged saphenous-vein bleeding times, which are consistent with

272 tion in patients with in-stent restenosis of saphenous-vein bypass grafts.

273 The saphenous-vein graft is the most common conduit for coro

274 of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse

275 number of arterial grafts into the LIMA plus saphenous veins (LIMA/SV) group (n=7435) or the MultArt

276 s of culture, the I/M ratio increased in the saphenous veins (P=0.03, P=0.04 versus 0 day, respective

277 Internal mammary arteries (IMAs) and saphenous veins (SVs) were collected at the time of card

278 tylcholine and bradykinin were determined in saphenous veins and internal mammary arteries from 117 p

279 superoxide production was quantified in both saphenous veins and internal mammary arteries from 45 di

280 F, and total homocysteine were determined in saphenous veins and internal mammary arteries obtained d

281 Samples of saphenous veins and internal mammary arteries were colle

282 sma and vascular biopterins (P<0.05 for both saphenous veins and internal mammary arteries).

283 In ex vivo experiments with human saphenous veins and internal mammary arteries, adiponect

284 henous veins before organ culture and in pig saphenous veins before interposition grafting into carot

285 essed TIMP-3 at the luminal surface of human saphenous veins before organ culture and in pig saphenou

286 Limitations in the long-term patency of saphenous veins for bypass grafts have encouraged intere

287 factor (VWF) by immunofluorescence in great saphenous veins harvested at cardiac bypass surgery.

288 P)H oxidase activity was determined in human saphenous veins obtained from 110 patients with coronary

289 peroxide production were determined in human saphenous veins obtained from 133 patients with coronary

290 nsfers to inhibit intimal hyperplasia in the saphenous veins was evaluated.

291 3.8+/-0.8% in the internal mammary arteries, saphenous veins, and normal coronary arteries, respectiv

292 istance arteries, internal mammary arteries, saphenous veins, and small subcutaneous veins were studi

293 f 100 sternotomy CABG patients using IMA and saphenous veins, both treating equivalent number of targ

294 l of intimal hyperplasia, we incubated human saphenous veins, internal mammary arteries, and radial a

295 In ex vivo experiments with human saphenous veins/internal mammary arteries and adipose ti

296 -C protein was not detected in control human saphenous veins; however, it was uniformly and strongly

297 nts provide effective treatment for stenotic saphenous venous aorto-coronary bypass grafts, but their

298 mal proliferation, sclerosis of arterialized saphenous venous graft, and fibromuscular dysplasia) rev

299 50% or greater in a native coronary artery, saphenous venous graft, or arterial bypass conduit, and

300 embolic protection group during treatment of saphenous venous grafts (SVGs).